REP-1 acts in all cells to enable the lipid modification (geranylgeranylation, a form of prenylation) of the
Ras-related GTPases known as Rabs, allowing for their function as regulators of intracellular trafficking pathways and phagosome fusion and maturation.
6 Rabs require prenylation by Rab geranylgeranyl-transferase (RabGGTase) for their activity, but unlike the other prenyltransferases, RabGGTase must complex with REPs, which perform the role of substrate recognition.
7 A related protein, REP-2, encoded by the autosomal gene
CHML (choroideremia-like), shares over 75% identity with REP-1, and also functions as a chaperone in the same prenylation pathway.
8 The ubiquitous expression profile of REP-1 and the essential role of Rab prenylation could suggest that CHM may also result in systemic abnormalities.
9,10 While certain Rabs have indeed been associated with syndromic diseases such as Griscelli syndrome type 2 (Rab27) and Charcot-Marie-Tooth disease type 2B (Rab7),
11,12 CHM has been viewed as a retinal disease, with no significant nonocular symptoms reported in males or carrier females. Previous work has demonstrated that a loss of REP-1 in fibroblasts and monocytes affected intracellular transport, increased pH levels in lysosomes, impaired proteolytic degradation, and altered secretion of cytokines, but these effects did not appear to translate to wider systemic effects.
13 Patients' apparent lack of nonocular symptoms or signs has been understood to result not from tissue-specific expression of REP-1, but from the differing affinities of REP-1 and REP-2 for target Rabs, such as Rab27 and Rab38, which may themselves be differentially expressed or possess tissue- or cell-specific activity.
14,15 Research proposes that a lack of REP-1 leads to defects in opsin transport to photoreceptor outer segments, the movement of RPE melanosomes, and the ability of the RPE to phagocytose photoreceptor outer segments.
16 These data suggest a compensatory mechanism by REP-2 in systems other than the eye.